Expertise in
10
conditions

Dr. David L. Paterson

Internal Medicine
UPMC Montefiore
3459 5th Ave, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
UPMC Montefiore
3459 5th Ave, 
Pittsburgh, PA 

Overview

David Paterson is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania.

Dr. Paterson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Sepsis, Pseudomonas Stutzeri Infections, Urinary Tract Infection (UTI), and Methicillin-Resistant Staphylococcus Aureus (MRSA).

He is actively involved in clinical research, co-authoring 530 peer reviewed articles and participating in 9 clinical trials.

Specialties

Internal Medicine

Licenses

Specialist in PA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Highmark
  • EPO
  • HMO
  • PPO

Locations

UPMC Montefiore
3459 5th Ave, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Staphylococcus Aureus Network Adaptive Platform Trial
Staphylococcus Aureus Network Adaptive Platform Trial
Enrollment Status: Recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Cefazolin, Penicillin, Clindamycin, Vancomycin
Study Phase: Phase 4
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Drug
Study Drugs: Gepotidacin, Nitrofurantoin
Study Phase: Phase 3
A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales
A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales
Enrollment Status: Withdrawn
Publish Date: May 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial
Enrollment Status: Terminated
Publish Date: December 19, 2018
Intervention Type: Drug
Study Phase: Phase 3
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol
Enrollment Status: Completed
Publish Date: June 14, 2018
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients; a Comparative Study With a Non-transplant Population
Enrollment Status: Completed
Publish Date: June 12, 2018
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
Enrollment Status: Completed
Publish Date: June 12, 2018
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.
Enrollment Status: Terminated
Publish Date: November 27, 2017
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

530 Total Publications

Bacteremia evaluation with T2 magnetic resonance in the emergency room (BETTER).
Bacteremia evaluation with T2 magnetic resonance in the emergency room (BETTER).
Journal: Microbiology spectrum
Published: July 15, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Margaret V. Ragni
Internal Medicine
Expertise in
7
conditions
Dr. Margaret V. Ragni
Internal Medicine

Hillman Center Pharmacy

5115 Centre Ave, 
Pittsburgh, PA 
 (1.4 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances

Margaret Ragni is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania. Dr. Ragni is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Von Willebrand Disease (VWD), Hemophilia B, and Liver Transplant.

Expertise in
22
conditions
Dr. Prashant K. Sharma
Internal Medicine
Expertise in
22
conditions
Dr. Prashant K. Sharma
Internal Medicine

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (2.5 miles away)
412-359-3030
Languages Spoken:
English
See accepted insurances

Prashant Sharma is a primary care provider, practicing in Internal Medicine in Pittsburgh, Pennsylvania. Dr. Sharma is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Thalassemia, Anemia, Hemolytic Anemia, Penectomy, and Knee Replacement.

Expertise in
82
conditions
Dr. Francis R. Colangelo
Internal Medicine
Expertise in
82
conditions
Dr. Francis R. Colangelo
Internal Medicine
Before you request

Office

3824 Northern Pike Ste 200, 
Monroeville, PA 
 (10.6 miles away)
412-380-2800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francis Colangelo is a primary care provider, practicing in Internal Medicine in Monroeville, Pennsylvania. Dr. Colangelo is highly rated in 82 conditions, according to our data. His clinical expertise encompasses Type 2 Diabetes (T2D), Hypertension, High Cholesterol, and Familial Hypertension.

Frequently Asked Questions about Dr. David L. Paterson

How do I make an appointment with Dr. David L. Paterson?

You can book an appointment with Dr. David L. Paterson by calling their office at 412-643-6401. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David L. Paterson a top-rated expert for Sepsis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David L. Paterson is classified as an Distinguished expert for Sepsis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David L. Paterson specialize in?

While Dr. David L. Paterson is a Internal Medicine, they have specific expertise in Sepsis, Pseudomonas Stutzeri Infections, and Urinary Tract Infection (UTI). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David L. Paterson participate in research or clinical trials?

Yes. Dr. David L. Paterson has published 530 articles and abstracts on conditions like Sepsis. You can view a list of Dr. David L. Paterson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David L. Paterson accept my insurance?

Dr. David L. Paterson accepts most major insurance plans, including Highmark. We recommend calling the office directly at 412-643-6401 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Paterson's expertise for a condition
ConditionClose
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile